| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90d41c5c08b4cc27008c8d448154a71f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf6afdc16ee5518854b0e3299d734662 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2021-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c7287b5a866702dd1a7b683d2e6b18e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88f45f9b7979306caca04bbe9fabd2ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc03bbae27e783dc71c90fefd91d18be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f9f03c135075df62ad83317212fad4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8798dbc00f3a93c5e9d27b42ee6ee4e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7772c45f1b4c74d2a162ef6d01df927
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a75708aeea25e91ea939052c5dafe7b |
| publicationDate |
2021-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021156326-A1 |
| titleOfInvention |
Antibodies for use in therapy |
| abstract |
The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023057535-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022128546-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023057534-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023146394-A1 |
| priorityDate |
2020-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |